



SUPERIOR COURT OF JUSTICE

COUNSEL SLIP

COURT FILE NO.: CV-23-00693595-00CL

DATE: 30-May-2023

NO. ON LIST: 1

TITLE OF PROCEEDING: **ACERUS PHARMACEUTICALS CORPORATION et al v. DAY et al**

BEFORE JUSTICE: **PENNY**

PARTICIPANT INFORMATION

For Plaintiff, Applicant, Moving Party, Crown:

Name of Person Appearing	Name of Party	Contact Info
Elizabeth Pillon	Lawyers for the Applicants	lpillon@stikeman.com
Lee Nicholson		leenicholson@stikeman.com
Philip Yang		pyang@stikeman.com
Allen Yao	Court-appointed Monitor of the Applicants	allen.yao@parthenon.ey.com
Alex Morrison		Alex.F.Morrison@parthenon.ey.com

For Defendant, Respondent, Responding Party, Defence:

Name of Person Appearing	Name of Party	Contact Info
Alexander Soutter	Lawyers for Jones Day	asoutter@tgf.ca
D.J. Miller		djmiller@tgf.ca

For Other, Self-Represented:

Name of Person Appearing	Name of Party	Contact Info
Stuart Brotman	Lawyer for the Monitor	sbrotman@fasken.com
Mervyn D. Abramowitz		mabramowitz@blaney.com
Mitch Stephenson	Lawyer for the Monitor	mstephenson@fasken.com
Troels Keldmann		troels@keldmann.dk
Naveed Manzoor		Naveed@faanadvisors.com

Xiaodi Jin		xjin@blg.com
Kristina Bezprozvannykh		kbezp@dv-law.com
Brian Gilderman	Precision Clinical Research, Inc.,	briang@PCRFLORIDA.COM

ENDORSEMENT OF HONOURABLE JUSTICE PENNY:

The applicants move for a sale approval and reverse vesting order, as well as a stay extension, to allow time to close the proposed transaction, and other ancillary relief.

I am satisfied that the requirements for approval of the proposed sale have been met and that the circumstances warrant the grant of a reverse vesting order. The extension of the stay is warranted, as is the ancillary relief requested.

My explanation for these conclusions, and discussion of some of the unique circumstances of this case, will be addressed in written reasons to follow.

Order to issue in the form signed by me this day.


Penny J.